ストックスクリーナーアプリを入手
37.75
0.91%
0.34
アフターアワーズ：
38.50
0.75
+1.99%
Urogen Pharma Ltd (URGN) 最新ニュース
UroGen Pharma Ltd focuses on bladder cancer therapies as investors watch long-term prospects - AD HOC NEWS
URGN stock stays tied to UroGen Pharma's pipeline - AD HOC NEWS
UroGen Pharma (URGN) Stock Looks Overvalued As 257% Returns Raise The Bar - Sahm
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares? - The Motley Fool
UroGen Pharma (URGN) Surges 4.24% as Shares Approach Key Resistance LevelCombination Correction - dars.gov.et
UroGen Pharma stock consolidates below 52-week high amid sustained bullish momentum - Traders Union
UroGen Pharma edges higher to $34.88 as leadership highlights integrity focus, UroGen Pharma - Traders Union
Urogen Pharma stock hits 52-week high at 36.12 USD By Investing.com - Investing.com South Africa
Urogen Pharma stock hits 52-week high at 36.12 USD - Investing.com
Price to book forward of UroGen Pharma Ltd. – NASDAQ:URGN - TradingView
(URGN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Price to book forward of UroGen Pharma Ltd. – SWB:UR8 - TradingView
Price to sales forward of UroGen Pharma Ltd. – SWB:UR8 - TradingView
Price to book forward of UroGen Pharma Ltd. – BOATS:URGN - TradingView
UroGen settles with Teva over Jelmyto patent dispute - MSN
Enterprise value to revenue forward of UroGen Pharma Ltd. – SWB:UR8 - TradingView
Price to earnings forward of UroGen Pharma Ltd. – BOATS:URGN - TradingView
Enterprise value to EBIT forward of UroGen Pharma Ltd. – NASDAQ:URGN - TradingView
Enterprise value to EBIT forward of UroGen Pharma Ltd. – SWB:UR8 - TradingView
URGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
UroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Gro - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
URGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Enterprise value to EBITDA forward of UroGen Pharma Ltd. – BOATS:URGN - TradingView
UroGen Pharma Ltd. Actuals & Estimates (NASDAQ:URGN) - TradingView
URGN Forecast — Price Target — Prediction for 2027 - TradingView
Urogen pharma CMO Mark Schoenberg sells $350,100 in shares By Investing.com - Investing.com Nigeria
Form 4 Urogen Pharma Ltd For: 24 June By Investing.com - Investing.com Australia
Urogen pharma CMO Mark Schoenberg sells $350,100 in shares - Investing.com
UroGen Pharma (URGN) CMO sells 10,000 shares in planned open-market trade - Stock Titan
UroGen Pharma (URGN) director receives new RSUs and stock option grant - Stock Titan
UroGen Pharma (URGN) director awarded 8,000 RSUs and 10,000 options - Stock Titan
UroGen Pharma (URGN) director receives 20,000 stock options at $34.99 strike - Stock Titan
[Form 4] UroGen Pharma Ltd. Insider Trading Activity - Stock Titan
UroGen Pharma (URGN) awards director RSUs and stock options - Stock Titan
Director at UroGen Pharma (NASDAQ: URGN) granted RSUs and stock options - Stock Titan
Form 144 UroGen Pharma Ltd. For: 22 June By Investing.com - Investing.com Australia
UroGen shareholders approve director insurance amendment and 2017 Plan increase - TradingView
UroGen Pharma (NASDAQ: URGN) OKs new articles and equity plan share increase - Stock Titan
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares? - AOL.com
Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsight - Yahoo Finance
UroGen Pharma (URGN) Form 144: Director sale of 10,000 shares for $300K - Stock Titan
UroGen Pharma StockSaturday overview of strategy and pipeline - Ad-hoc-news.de
1.17%
2.48%
大文字化:
|
ボリューム (24 時間):